With rising demand for stereo-, chemo-, and regioselective chiral molecule synthesis, interest in biocatalysis has also grown. In particular, cell-free biosynthesis (CFB), the in vitro use of enzymes in chemical synthesis, has gained popularity in recent years due to its higher yields and specificity and lower environmental impact than current synthetic techniques. This method also offers improved yields and resistance to toxicity relative to in vivo biosynthesis by removing cellular metabolic requirements and burdens. However, the cost of CFB is still a significant drawback, with enzyme cofactors representing a significant fraction of the reaction setup price tag.